PA programs: missing the target

Benefits Canada (March 2011)

Between 1998 and 2008, the most popular topic of conversation in drug plan management was the brave new world of expensive specialty (i.e. biological) drugs. As everybody knows, the fear was that these revolutionary new therapies would hit plans and drive costs to unsustainable levels. The only problem was that during that period, it never happened—at least not for a vast majority of plans. Download PDF


Latest News